News
2026/10/10
JeYou Pharma's AR-NTD Inhibitor Clinical Trial Application Approved
Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the clinical trial application for its self-developed AR-NTD inhibitor, the JMN-2205 tablet project, has been approved...
Details
21
2026/01
Breaking News | $2.2 Billion! GSK Sets Sights on Jeyou’s Core Asset JYB1904; Roche and GSK Demonstrate Dual Breakthroughs in “Small and Large Molecules”
[Abstract] Global pharmaceutical giant GSK has announced the acquisition of RAPT Therapeutics, the U.S. partner of Jeyou Pharmaceutical, for approximately $2.2 billion. The core of the deal centers on JYB1904, an innovative macromolecular drug independently developed by Jeyou Pharmaceutical. Following the interest shown by Roche in its small-molecule pipeline candidate JMKX002992,Jeyou Pharma has now secured substantial backing from GSK in the large-molecule sector. This marks Jeyou as one of the few domestic innovative drug companies capable of delivering “global-class” products in both the small-molecule and large-molecule fields.
20
2026/01
Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, Led a Delegation on a Visit to Jeyou Pharmaceutical: Government and Enterprise Join Forces to Chart a Course for Innovation in the Biopharmaceuti
On January 19, 2026, Xu Lei, Member of the Standing Committee of the Pudong New Area Party Committee and Deputy District Governor, led a delegation to Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) for an on-site inspection. The two sides engaged in in-depth discussions on topics including deepening government-enterprise cooperation, accelerating the commercialization of innovative achievements, and optimizing the business environment.
21
2025/10
Jeyou Pharma and RAPT Therapeutics Jointly Announce Positive Top-Line Results from the Phase 2 Clinical Trial of JYB1904 (RPT904) for the Treatment of Chronic Spontaneous Urticaria
Under both the Q8W and Q12W dosing regimens, the efficacy and safety of JYB1904 were comparable to those of omazulizumab administered every 4 weeks. The effects of a single dose of JYB1904 persisted through Week 16. Tolerability was good, and no serious adverse events related to the study drug were observed……
01
2025/07
Notice Regarding the Renaming of “Jeyou Pharmaceutical”
Thanks to your continued trust and support of Jeyou Pharmaceuticals, we have been able to grow rapidly...
23
2024/12
Jeyou Pharma and RAPT Announce Exclusive Licensing Agreement for a Novel Long-Acting IgE Antibody
Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharmaceutical”) has entered into an exclusive licensing agreement with RAPT Therapeutics (hereinafter referred to as “RAPT”), under which Jeyou Pharmaceutical has granted RAPT an exclusive license for the global development and commercialization of JYB1904—a novel long-acting IgE antibody with proprietary intellectual property rights—outside of Greater China……
09
2024/01
Jeyou Pharma's innovative monoclonal antibody JYB1904 Receives Approval for Clinical Trials in a New Indication
The new indication is chronic spontaneous urticaria; the previously approved treatment for moderate-to-severe allergic asthma has completed Phase I trials……